Bioinformatics Prediction and in vivo Verification Identify SLC7A5 as Immune Infiltration Related Biomarker in Breast Cancer

Purpose: Solute carrier family 7, member 5 (SLC7A5) is reportedly a key gene in various tumors. However, the relationship between SLC7A5 and immune cell infltration in breast cancer remains elusive. In this study, we investigated the expression levels and clinical value of SLC7A5 using the R package...

Full description

Saved in:
Bibliographic Details
Published in:Cancer management and research 2022-01, Vol.14, p.2545-2559
Main Authors: Zhu, Qiannan, Wang, Jue, Shi, Yuenian, Zha, Xiaoming, Wang, Shui
Format: Article
Language:English
Subjects:
Algorithms
Amino acids
Analysis
Bioinformatics
Biomarkers
Breast cancer
Cell growth
chemosensitivity
Cytokines
Datasets
Genomes
immune cell infiltration
Medical diagnosis
Medical prognosis
Metastasis
Original Research
Physiological aspects
Prognosis
Proteins
slc7a5
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose: Solute carrier family 7, member 5 (SLC7A5) is reportedly a key gene in various tumors. However, the relationship between SLC7A5 and immune cell infltration in breast cancer remains elusive. In this study, we investigated the expression levels and clinical value of SLC7A5 using the R package in breast cancer through the TCGA database. Methods: Public transcript data and clinical information of patients were downloaded from the TCGA database. Prognosis analysis was performed to explore the clinical value of SLC7A5 as well as drug sensitivity prediction and Gene Set Enrichment Analysis (GSEA). We also explored the correlations between SLC7A5 and immune infltration as well as immune markers. Results: We observed that high SLC7A5 expression levels were related to poor survival. Our GSEA demonstrated that G proteincoupled receptor-ligand binding, interleukin signaling, neutrophil degranulation, amino acid and derivative metabolism, and Rho GTPase signaling were differentially enriched in the SLC7A5 high-expression phenotype. Patients in the low SLC7A5 expression group showed sensitivity to paclitaxel and doxorubicin. Conclusion: SLC7A5 could serve as a biomarker for breast cancer prognosis. Keywords: SLC7A5, breast cancer, immune cell infltration, chemosensitivity
ISSN:1179-1322
1179-1322
DOI:10.2147/CMAR.S370397